Company
Headquarters: Hohhot, China
Employees: 1,444
CN¥7.34 Billion
CNY as of Jan. 1, 2025
US$1.01 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sales of veterinary biological products in China. It offers vaccines for foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever for pigs, poultry, ruminants, and pets. The company was formerly known as Inner Mongolia Jinyu Group Co., Ltd. and changed its name to Jinyu Bio-technology Co., Ltd. in December 2015. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥1.35 B |
| EBITDA | CN¥243.1 M |
| Gross Profit TTM | CN¥750.2 M |
| Profit Margin | 12.21% |
| Operating Margin | 10.89% |
| Quarterly Revenue Growth | -32.80% |
Jinyu Bio-technology Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600201 wb_incandescent